SlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2017Effectively Communicating Your Research Objectives in Grant Applications - S. Lewin, AO, FRACP, PhD, FAHMSView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2017Innovative ways to stimulate the demand of HIV and HCV testing- Philip CunninghamView Slideset
JRJürgen RockstrohMDSlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2017New hepatitis drugs- Jürgen Rockstroh, MDView Slideset
DKDaniel KuritzkesMDSlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2017New HIV drugs / regimens- Daniel Kuritzkes, MDView Slideset
MCMartin ChooMMedScSlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2017Barriers to access - Community perspective- Martin Choo, MMedScView Slideset
GKGiten KhwairakpamSlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2017Access to treatment/care on the country level- Giten KhwairakpamView Slideset
MHMargaret HellardAM, MBBS, FRACP, FAFPHM, PhDSlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2017Access to treatment/care on the global level- Margaret Hellard, AM, MBBS, FRACP, FAFPHM, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2017PrEP research and implementation gaps- Michael CassellView Slideset
RDRossana DitangcoMDSlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2017Round Table Discussion: Genuine supply from the providers- Rossana DitangcoView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2017Round Table Discussion: True demand from the communities- Midnigh PoonkasetwattanaView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2017Population-based PrEP implementation in New South Wales, Australia- Andrew GrulichView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2017Using a robust incentive-based, peer-centered model to identify new HIV cases among men who have sex with men, transgender women, and people who inject drugs in Cambodia- Dr. R. SophaView Slideset
